**Table 1, Supplementary material, Baseline characteristics**

|  |  |  |
| --- | --- | --- |
|  | **Before propensity score (PS) matching** | **After propensity score (PS) matching** |
|  | **Overall (N=1033)** | **Control(N=838)** | **Aspirin(N=195)** | **P-value** | **Overall (N=352)** | **Control(N=176)** | **Aspirin(N=176)** | **P-value** |
| **Age (Years), Mean (SD)** | 61.7 (14.77) | 60.4 (15.08) | 67.3 (11.89) | <.0001\* | 67.6 (12.86) | 67.8 (13.68) | 67.4 (12.02) | 0.9281^ |
| **Gender – Male, n (%)** | 689 ( 69.1 ) | 550 ( 68.2 ) | 139 ( 72.8 ) | 0.2224^^ | 238 ( 68.4 ) | 113 ( 64.9 ) | 125 ( 71.8 ) | 0.1665^^ |
| **Weight (kg), Mean (SD)** | 81.4 (18.72) | 81.1 (18.77) | 82.7 (18.54) | 0.2214^ | 79.4 (17.35) | 76.8 (15.48) | 82.1 (18.72) | 0.0058^ |
| **APACHE II score, Median (Q1,Q3)** | 14.0 (9.00, 22.00) | 14.0 (9.00, 23.00) | 14.0 (10.00, 21.00) | 0.4018^ | 15.0 (10.00, 22.00) | 15.0 (10.00, 25.00) | 14.5 (10.00, 21.00) | 0.3867^ |
| **SOFA score, Median (Q1,Q3)** | 5.0 (3.00, 8.00) | 5.0 (3.00, 7.00) | 5.0 (3.00, 9.00) | 0.0226^ | 5.0 (3.00, 8.00) | 5.0 (3.00, 7.00) | 5.0 (3.00, 9.00) | 0.2092^ |
| **Systemic Corticosteroids use, n (%)** | 886 ( 89.9 ) | 716 ( 89.7 ) | 170 ( 90.9 ) | 0.6277^^ | 315 ( 91.3 ) | 159 ( 91.4 ) | 156 ( 91.2 ) | 0.9602^^ |
| **Tocilizumab use, n (%)** | 358 ( 36.2 ) | 295 ( 36.9 ) | 63 ( 33.3 ) | 0.3561^^ | 111 ( 31.8 ) | 53 ( 30.3 ) | 58 ( 33.3 ) | 0.5410^^ |
| **Estimated glomerular filtration rate (eGFR) Baseline, Median (Q1,Q3)** | 76.0 (45.00, 97.00) | 77.0 (48.00, 98.00) | 68.0 (38.00, 93.00) | 0.0341^ | 66.0 (38.00, 92.00) | 64.0 (38.00, 92.00) | 68.0 (38.00, 92.00) | 0.8786^ |
| **Acute Kidney Injury (AKI) within 24 hours of ICU admission, n (%)** | 244 ( 25.0 ) | 191 ( 24.2 ) | 53 ( 28.5 ) | 0.2212^^ | 113 ( 32.4 ) | 62 ( 35.4 ) | 51 ( 29.3 ) | 0.2220^^ |
| **Mechanical Ventilation within 24 hours of ICU admission , n (%)** | 702 ( 70.0 ) | 558 ( 68.6 ) | 144 ( 75.8 ) | 0.0527^^ | 260 ( 74.5 ) | 128 ( 73.1 ) | 132 ( 75.9 ) | 0.5601^^ |
| **Oxygenation Index (OI)** | 15.9 (8.40, 24.50) | 15.5 (8.40, 24.54) | 18.5 (7.64, 24.28) | 0.6466^ | 18.7 (7.64, 29.95) | 18.2 (7.10, 35.27) | 19.2 (7.64, 24.28) | 0.5484^ |
| **Lactic acid Baseline (mmol/L), Median (Q1, Q3)** | 1.7 (1.25, 2.31) | 1.6 (1.24, 2.30) | 1.7 (1.26, 2.42) | 0.5358^ | 1.7 (1.30, 2.49) | 1.7 (1.30, 2.46) | 1.7 (1.26, 2.56) | 0.8720^ |
| **Platelets count Baseline (10^9/L), Median (Q1, Q3)** | 242.0 (185.00, 310.00) | 243.5 (188.00, 308.00) | 234.0 (175.00, 319.00) | 0.4117^ | 244.0 (179.00, 313.00) | 255.0 (192.00, 312.00) | 231.0 (173.50, 318.00) | 0.1688^ |
| **Total WBC Baseline (10^9/L), Median (Q1, Q3)** | 9.6 (6.73, 12.90) | 9.6 (6.59, 12.80) | 9.6 (6.95, 13.00) | 0.4859^ | 9.7 (7.15, 13.60) | 9.9 (7.36, 14.00) | 9.5 (7.01, 13.03) | 0.3676^ |
| **International normalized ratio (INR), Median (Q1,Q3)** | 1.1 (1.03, 1.20) | 1.1 (1.03, 1.21) | 1.1 (1.02, 1.19) | 0.0893^ | 1.1 (1.03, 1.23) | 1.1 (1.04, 1.26) | 1.1 (1.02, 1.19) | 0.0182^ |
| **Activated partial thromboplastin time (aPTT) Baseline (Seconds), Median (Q1, Q3)** | 30.3 (27.00, 33.90) | 30.5 (27.00, 34.00) | 29.9 (26.70, 33.30) | 0.3951^ | 30.5 (27.00, 34.40) | 30.6 (27.10, 35.60) | 30.0 (26.70, 33.30) | 0.2143^ |
| **Total bilirubin (μmol/L), Median (Q1, Q3)** | 9.8 (6.80, 14.00) | 9.8 (6.80, 14.00) | 9.7 (6.50, 15.20) | 0.8539^ | 9.8 (6.60, 14.80) | 10.0 (6.60, 14.40) | 9.6 (6.60, 15.20) | 0.9610^ |
| **Albumin Baseline (gm/L), Median (Q1, Q3)** | 32.5 (28.00, 36.00) | 33.0 (28.00, 36.30) | 32.0 (29.00, 35.00) | 0.3546^ | 32.0 (28.00, 35.90) | 33.0 (28.00, 36.00) | 32.0 (29.00, 35.00) | 0.7768^ |
| **Creatine phosphokinase (CPK) baseline (U/l), Median (Q1,Q3)** | 172.0 (76.00, 421.00) | 170.5 (77.00, 403.00) | 190.0 (72.00, 508.00) | 0.5002^ | 153.0 (67.00, 399.00) | 124.0 (59.00, 267.00) | 200.0 (76.00, 508.00) | 0.0127^ |
| **C-reactive protein (CRP) baseline (mg/l)m Median (Q1,Q3)** | 129.0 (64.37, 196.20) | 127.0 (63.80, 193.00) | 134.5 (73.00, 220.00) | 0.1943^ | 132.0 (66.00, 199.00) | 129.0 (55.40, 199.00) | 134.0 (69.00, 199.00) | 0.5324^ |
| **Procalcitonin (ng/ml), Median (Q1,Q3)** | 0.4 (0.14, 1.08) | 0.3 (0.14, 1.05) | 0.4 (0.13, 1.24) | 0.8457^ | 0.4 (0.14, 1.46) | 0.4 (0.16, 1.66) | 0.4 (0.13, 1.24) | 0.4061^ |
| **Fibrinogen Level baseline (gm/l), Median (Q1,Q3)**  | 5.4 (3.77, 7.18) | 5.5 (3.77, 7.18) | 5.3 (3.80, 7.38) | 0.9787^ | 5.2 (3.60, 7.23) | 5.1 (3.77, 6.80) | 5.3 (3.10, 7.51) | 0.4437^ |
| **D-dimer Level baseline (mg/l), Median (Q1,Q3)**  | 1.3 (0.71, 3.27) | 1.3 (0.71, 3.40) | 1.3 (0.70, 2.51) | 0.6422^ | 1.4 (0.74, 3.48) | 1.4 (0.77, 3.83) | 1.3 (0.70, 2.51) | 0.3255^ |
| **DVT prophylaxis - Low, n (%)** | 84 ( 9.3 ) | 62 ( 8.6 ) | 22 ( 12.1 ) | 0.3613^^ | 39 ( 12.1 ) | 17 ( 10.8 ) | 22 ( 13.3 ) | 0.6994^^ |
| **DVT prophylaxis - Standard, n (%)** | 466 ( 51.8 ) | 375 ( 52.3 ) | 91 ( 50.0 ) | 0.3613^^ | 164 ( 50.8 ) | 83 ( 52.9 ) | 81 ( 48.8 ) | 0.6994^^ |
| **DVT prophylaxis - High, n (%)** | 349 ( 38.8 ) | 280 ( 39.1 ) | 69 ( 37.9 ) | 0.3613^^ | 120 ( 37.2 ) | 57 ( 36.3 ) | 63 ( 38.0 ) | 0.6994^^ |
| **Ferritin (ug/l), Median (Q1, Q3)** | 782.5 (383.95, 1621.50) | 822.3 (400.10, 1650.00) | 635.6 (296.00, 1301.00) | 0.0140^ | 659.3 (338.40, 1500.00) | 687.5 (386.50, 1650.00) | 602.3 (300.90, 1212.00) | 0.1259^ |
| **Blood sugar level (mmol/L) Baseline, Median (Q1, Q3)** | 11.2 (7.60, 15.60) | 10.8 (7.50, 15.00) | 12.6 (8.50, 17.40) | 0.0026^ | 12.5 (8.20, 17.00) | 12.3 (7.90, 16.80) | 12.6 (8.40, 17.30) | 0.7654^ |
| **PaO2/FiO2 ratio within 24 hours of admission, Median (Q1,Q3)** | 83.3 (60.20, 135.80) | 85.0 (60.00, 140.20) | 81.4 (63.50, 124.00) | 0.5872^ | 80.0 (58.60, 126.40) | 78.6 (55.33, 142.50) | 81.6 (63.50, 121.40) | 0.5284^ |
| **Respiratory Rate (RR/minute) Baseline, Median (Q1,Q3)** | 28.0 (23.00, 33.00) | 28.0 (23.00, 33.00) | 27.0 (23.00, 32.00) | 0.4461^ | 27.0 (22.00, 33.00) | 28.0 (22.00, 33.50) | 26.5 (23.00, 32.00) | 0.8407^ |
| **Maximum temperature Baseline (C°), Median (Q1, Q3)** | 37.4 (37.00, 38.10) | 37.4 (37.00, 38.10) | 37.3 (37.00, 38.10) | 0.4209^ | 37.3 (37.00, 38.00) | 37.3 (37.00, 38.00) | 37.4 (37.00, 38.10) | 0.3917^ |
| **Prone position status, n (%)** | 296 ( 30.4 ) | 254 ( 32.1 ) | 42 ( 23.1 ) | 0.0174^^ | 74 ( 21.2 ) | 34 ( 19.4 ) | 40 ( 23.0 ) | 0.4159^^ |
| **Patient received nephrotoxic drugs/material during ICU stay, n (%)** | 808 ( 81.4 ) | 641 ( 79.5 ) | 167 ( 89.3 ) | 0.0020^^ | 292 ( 84.6 ) | 140 ( 80.5 ) | 152 ( 88.9 ) | 0.0299^^ |
| **Comorbidity** |  |  |  |  |  |  |  |  |
| Atrial fibrillation (A Fib)**, n (%)** | 27 ( 2.7 ) | 25 ( 3.1 ) | 2 ( 1.0 ) | 0.1195^^ | 15 ( 4.3 ) | 13 ( 7.4 ) | 2 ( 1.1 ) | 0.0038^^ |
| Heart Failure**, n (%)** | 84 ( 8.4 ) | 60 ( 7.4 ) | 24 ( 12.6 ) | 0.0196^^ | 44 ( 12.6 ) | 21 ( 12.0 ) | 23 ( 13.2 ) | 0.7317^^ |
| Hypertension**, n (%)** | 558 ( 55.5 ) | 406 ( 49.9 ) | 152 ( 79.6 ) | <.0001^^ | 246 ( 70.5 ) | 103 ( 58.9 ) | 143 ( 82.2 ) | <.0001^^ |
| Diabetes mellitus**, n (%)** | 595 ( 59.2 ) | 458 ( 56.3 ) | 137 ( 71.7 ) | <.0001^^ | 241 ( 69.1 ) | 113 ( 64.6 ) | 128 ( 73.6 ) | 0.0692^^ |
| Dyslipidemia, **n (%)** | 196 ( 19.5 ) | 120 ( 14.7 ) | 76 ( 39.8 ) | <.0001^^ | 88 ( 25.2 ) | 20 ( 11.4 ) | 68 ( 39.1 ) | <.0001^^ |
| Ischemic heart disease (IHD)**, n (%)** | 85 ( 8.5 ) | 56 ( 6.9 ) | 29 ( 15.2 ) | 0.0002^^ | 46 ( 13.2 ) | 23 ( 13.1 ) | 23 ( 13.2 ) | 0.9834^^ |
| Chronic kidney disease (CKD) **, n (%)** | 111 ( 11.0 ) | 78 ( 9.6 ) | 33 ( 17.3 ) | 0.0023^^ | 47 ( 13.5 ) | 16 ( 9.1 ) | 31 ( 17.8 ) | 0.0176^^ |
| Cancer**, n (%)** | 23 ( 2.3 ) | 18 ( 2.2 ) | 5 ( 2.6 ) | 0.7353\*\* | 9 ( 2.6 ) | 4 ( 2.3 ) | 5 ( 2.9 ) | 0.7290\*\* |
| Acute Coronary Syndrome (ACS)**, n (%)** | 14 ( 1.4 ) | 8 ( 1.0 ) | 6 ( 3.1 ) | 0.0220\*\* | 9 ( 2.6 ) | 3 ( 1.7 ) | 6 ( 3.4 ) | 0.3068\*\* |
| Deep vein thrombosis**, n (%)** | 5 ( 0.5 ) | 5 ( 0.6 ) | 0 ( 0.0 ) | 0.2775\*\* | 0 (0.0) | 0 (0.0) | 0 (0.0) | NA |
| Pulmonary embolism**, n (%)** | 6 ( 0.6 ) | 5 ( 0.6 ) | 1 ( 0.5 ) | 0.8836\*\* | 2 ( 0.6 ) | 1 ( 0.6 ) | 1 ( 0.6 ) | 0.9968\*\* |
| Liver disease (any type) **, n (%)** | 19 ( 1.9 ) | 14 ( 1.7 ) | 5 ( 2.6 ) | 0.4122\*\* | 8 ( 2.3 ) | 3 ( 1.7 ) | 5 ( 2.9 ) | 0.4693\*\* |
| Stroke**, n (%)** | 54 ( 5.4 ) | 34 ( 4.2 ) | 20 ( 10.5 ) | 0.0005^^ | 37 ( 10.6 ) | 19 ( 10.9 ) | 18 ( 10.3 ) | 0.8765^^ |
| \*T Test / ^ Wilcoxon rank sum test is used to calculate the P-value.^^ Chi square/ \*\* Fisher’s Exact teat is used to calculate P-value. |